When it’s time to start your patient on his first basal insulin

  • He may be reluctant—he feels insulin may be too complicated
  • He wonders if he can afford the medicine
  • He’s not to goal on non-insulin therapy, and his A1C continues to rise

About 31% of new prescriptions for diabetes drugs are not filled a first time.1

See what the BASAGLAR® (insulin glargine) injection 100 units/mL Experience resources offer

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental mix-ups between insulin products have been reported. To avoid hypoglycemia due to medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.

Backed by savings and support

BASAGLAR comes with options* that may help make insulin therapy more affordable.

With a monthly savings card, BASAGLAR may help your eligible commercially insured patients get off to a good start and help keep the cost to as little as $25 per month.

*For eligible patients.

Offer good until 12/31/2022 for up to 24 fills. Patient must have commercial drug insurance with insurance provider coverage for BASAGLAR to pay as little as $25 for a 30-day supply of BASAGLAR. Offer subject to a monthly cap of $100 and a separate annual cap of $1200. Offer void where prohibited by law. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or whose prescription claims for BASAGLAR are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

Each card has a unique ID number. Please do not make copies.

Select the number of cards you need

Lilly may be able to help those patients who are not eligible for a BASAGLAR Savings Card or need additional assistance. Call the Lilly Diabetes Solution Center at 1-833-808-1234.

Lilly is committed to helping people with diabetes regardless of whether they have insurance from an employer, Medicare, or no insurance at all. Visit insulinaffordability.com for information on:

  • The Lilly Diabetes Solution Center, offering confidential conversations with patients to determine their eligibility for solutions based on their circumstances
  • Discount programs
  • Savings cards
  • Medicare coverage
Visit insulinaffordability.com

SELECT IMPORTANT SAFETY INFORMATION

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose.

The risk of hypoglycemia may increase when antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics are co-administered with BASAGLAR.

The blood glucose lowering effect of BASAGLAR may decrease when co-administered with atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. The blood glucose lowering effect of BASAGLAR may increase or decrease when co-administered with alcohol, beta-blockers, clonidine, lithium salts, and pentamidine.

The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with BASAGLAR.

Resources designed to be simple

BASAGLAR comes with the BASAGLAR Experience: resources designed to help patients accept, start, and stay on insulin.

In patients with type 1 diabetes, BASAGLAR must be used concomitantly with short-acting insulin.2

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.

ACCEPT: Support for your hesitant patients

Are concerns and misconceptions about insulin preventing your patients from starting? When A1C is rising and a patient is still hesitant about starting basal insulin, the BASAGLAR Experience resources may help.

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

All insulins, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.

START: Resources are designed to help your patients first starting basal insulin

We have resources that are designed to help with your patient's transition to insulin.

BASAGLAR Sample Kit with needles

Lilly is committed to providing the BASAGLAR sample kit to physicians as a resource for patients starting basal insulin. The BASAGLAR sample kit includes a prefilled KwikPen and needles, plus information to access other resources:

  • Information about what to expect
  • Videos to watch for help with injections
  • Savings information
  • Phone number to call with questions and to get connected to the BASAGLAR GoodStart® Program

Train patients on proper use and injection technique before initiating BASAGLAR.

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Injection Instruction Video

  • A step-by-step demonstration on how to inject
  • Available online and as an in-office resource

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

ADVERSE REACTIONS

Adverse reactions commonly (>5%) associated with insulin glargine products are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.

BASAGLAR patient website

Patients can also access many resources on BASAGLAR.com, including the step-by-step Injection Instruction Video and the Instructional Brochure. The website also has:

  • Important phone numbers
  • Savings information
  • Spanish-language site with resources

SELECT IMPORTANT SAFETY INFORMATION

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose.

The risk of hypoglycemia may increase when antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics are co-administered with BASAGLAR.

The blood glucose lowering effect of BASAGLAR may decrease when co-administered with atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. The blood glucose lowering effect of BASAGLAR may increase or decrease when co-administered with alcohol, beta-blockers, clonidine, lithium salts, and pentamidine.

The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with BASAGLAR.

Visit BASAGLAR.com/es or contact your BASAGLAR representative for resources tailored for your Hispanic/Latino patients.

References:

  1. Fischer MA, Stedman MR, Lii J, et al. J Gen Intern Med. 2010;25(4):284-290.
  2. BASAGLAR [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.
  3. Data on file, Lilly USA, LLC. DOF-BV-US-0002.

INDICATION

BASAGLAR is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

LIMITATION OF USE

BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or any of the excipients in BASAGLAR.

WARNINGS AND PRECAUTIONS

BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. Due to reports of hypoglycemia and hyperglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.

Hypoglycemia is the most common adverse reaction associated with insulins, including BASAGLAR. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.

Accidental mix-ups between insulin products have been reported. To avoid hypoglycemia due to medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.

All insulins, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

ADVERSE REACTIONS

Adverse reactions commonly (>5%) associated with insulin glargine products are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose.

The risk of hypoglycemia may increase when antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics are co-administered with BASAGLAR.

The blood glucose lowering effect of BASAGLAR may decrease when co-administered with atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. The blood glucose lowering effect of BASAGLAR may increase or decrease when co-administered with alcohol, beta-blockers, clonidine, lithium salts, and pentamidine.

The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with BASAGLAR.

For more information, please see accompanying Full Prescribing Information and Patient Information. Please see Instructions for Use.

BV HCP ISI 27JUL2021